Saturday 17 October 2026
Export CELZ’s income statement to Excel — free account
Creative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 14.6% and free cash flow fell 27.1%, each against the same quarter a year earlier.
0.74
0.08
−9.76%
Follow CELZ
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 3 | 4 | 3 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(4.32) | (9.09) | 2.14 | (3.97) | (2.01) | (193.07) | (77.15) | 321.12 | 26,422.65 | — |
P/S ratio |
274.72 | 170.99 | 78.39 | 26.00 | 54.67 | 48.92 | 1,406.15 | 23,313.55 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(1.04) | (11.32) | 13.80 | (2.44) | 1.36 | (661.98) | (277.45) | (190.48) | (172.98) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | — | — | — | — | (67.22) | (105.78) | — | — |
P/Operating CF |
(2.41) | (1.75) | (3.42) | (1.13) | (4.96) | 141.44 | (922.02) | (9,807.93) | (779,882.64) | — |
P/B ratio |
0.62 | 0.54 | 0.63 | 0.26 | 0.56 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Tangible BV |
0.66 | 0.59 | 0.65 | 0.26 | 0.59 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
(142.33) | (120.12) | (41.09) | (26.44) | (46.05) | 53.13 | 1,412.04 | 23,316.59 | 0.00 | — |
EV/EBITDA |
0.40 | 0.43 | 0.61 | 0.41 | 0.00 | 0.00 | 376.74 | 17,547.39 | 0.00 | — |
EV/Operating CF |
0.41 | 0.45 | 0.42 | 0.53 | 2.19 | (20.11) | (192.64) | (2,756.42) | (107,567.26) | — |
EV/FCF |
0.22 | 0.23 | 0.25 | 0.31 | 1.88 | (11.00) | (192.64) | (2,756.42) | (107,567.26) | — |
Quick Ratio |
25.30 | 18.13 | 26.89 | 2.50 | 10.21 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
Current Ratio |
25.97 | 18.73 | 27.65 | 5.64 | 10.22 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
Net Debt/EBITDA |
1.20 | 1.05 | 1.81 | 0.82 | (9.54) | (10.14) | 1.57 | 2.29 | (0.28) | 0.13 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 109.88% | 200.13% | 142.94% | 124.37% | 39.57% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | (0.13) | (0.17) | (0.11) | (0.81) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.26 | 0.33 | 0.37 | 0.02 | 0.00 |
Operating CF/Net income |
0.98 | 0.97 | 1.52 | 0.77 | (0.12) | 0.01 | 0.14 | 0.08 | 0.33 | 0.58 |
Capex/Depreciation |
0.00 | (1.81) | (1.06) | 0.00 | 0.00 | (0.24) | 0.00 | 0.00 | 0.00 | (1.06) |
Interest Coverage |
— | — | — | — | (0.73) | (0.91) | (0.60) | (0.82) | (3.12) | (118.70) |
| (86.53%) | (65.85%) | (40.34%) | (77.78%) | (129.86%) | 151.73% | 140.55% | 438.12% | 222.15% | 1,414.77% | |
| (82.81%) | (63.20%) | (35.36%) | (66.62%) | 320.57% | (5,818.55%) | (1,683.27%) | (4,014.61%) | (1,011.83%) | (411.77%) | |
ROIC |
(1,213.03%) | (895.02%) | (984.74%) | (84.87%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(84.27%) | (94.59%) | (53.40%) | (65.76%) | 198.33% | 89.86% | 99.71% | 328.41% | 110.03% | 330.22% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 10.39 | 0.00 | 12.35 | 28.17 | 365.00 | — |
Research and Development Expense of Revenue |
37,663.33% | 21,825.45% | 21,895.56% | 7,075.51% | 124.37% | 0.00% | 0.00% | 77.65% | 5,418.75% | 0.00% |
Selling, General and Administrative Expense of Revenue |
62,725.00% | 29,447.27% | 39,558.89% | 4,450.90% | 3,376.42% | 706.32% | 739.09% | 844.45% | 18,718.75% | 0.00% |
Intangible Assets out of Total Assets |
0.05 | 0.08 | 0.04 | 0.02 | 0.05 | 0.86 | 0.82 | 0.34 | 0.91 | 0.31 |
Share Based Compensation of Revenue |
58.33% | 332.73% | 406.67% | 77.54% | 678.13% | 103.53% | 0.00% | 1.53% | 3,004.17% | 0.00% |
Graham Net Nets |
1.52 | 1.70 | 1.53 | 3.79 | 1.68 | (5.02) | (0.04) | 0.00 | 0.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 255.12 | 3,115.24 | 37.96 | 89.73 | 1.09 | — |
Earnings Yield |
(132.14%) | (160.61%) | (80.65%) | (262.78%) | 333.71% | (451.35%) | (3.65%) | (0.47%) | 0.00% | — |
Free Cash Flow Yield |
(239.34%) | (310.63%) | (208.48%) | (323.81%) | (44.74%) | (9.87%) | (0.52%) | (0.04%) | 0.00% | — |
Revenue per Share |
0.00 | 0.01 | 0.01 | 0.08 | 0.34 | 2.84 | 0.16 | 0.32 | 0.00 | 0.00 |
Operating CF per Share |
(2.46) | (3.58) | (5.70) | (7.13) | (8.51) | (7.51) | (1.17) | (2.69) | (0.08) | (0.05) |
Capex per Share |
0.00 | (0.14) | (0.07) | 0.00 | 0.00 | (4.32) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.46) | (3.72) | (5.77) | (7.13) | (8.51) | (11.82) | (1.17) | (2.69) | (0.08) | (0.05) |
Cash per Share |
3.03 | 4.01 | 7.10 | 7.61 | 41.17 | 1.69 | 0.09 | 0.78 | 0.00 | 0.02 |
Shareholders Equity per Share |
3.16 | 4.28 | 7.35 | 14.51 | 39.22 | (687.44) | (7.80) | (10.23) | (0.21) | (0.02) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.16 | 4.28 | 7.35 | 14.51 | 39.22 | (687.44) | (7.80) | (10.23) | (0.21) | (0.02) |
Free Cash Flow |
(5.86) | (5.50) | (8.13) | (7.80) | (2.22) | (0.68) | (1.21) | (1.05) | (0.89) | (0.46) |
Working Capital |
7.11 | 5.81 | 9.90 | 15.43 | 9.69 | (40.42) | (8.51) | (4.16) | (2.42) | (0.23) |
Capital Expenditures |
— | (0.20) | (0.10) | — | — | (0.25) | — | — | — | (0.01) |
Net Current Asset Value |
7.11 | 5.81 | 9.90 | 15.43 | 9.69 | (40.42) | (8.51) | (4.16) | (2.42) | (0.26) |
EV/EBIT |
0.39 | 0.42 | 0.60 | 0.40 | 1.55 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 18.18 | 11.11 | 0.00 | 0.00 | 1.52 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(39.75%) | (44.79%) | (39.98%) | (32.24%) | (10.58%) | 1.76% | 17.53% | 34.98% | 45.16% | (237.45%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 21.68 | 0.00 | 21.78 | 17.28 | 0.18 | — |
Accounts Payable Turnover |
0.01 | 0.01 | 0.00 | 0.01 | 0.09 | 0.15 | 0.14 | 0.25 | 0.05 | 0.00 |
Inventory Turnover |
0.00 | 1.00 | 0.43 | 2.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
44,911.59 | 22,688.07 | 32,170.69 | 41,846.93 | 5,805.71 | 2,531.20 | 2,573.45 | 1,720.27 | 10,840.50 | 2,578.30 |
Days of Inventory on Hand |
0.00 | 182.50 | 669.17 | 130.63 | 83.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | 0.00 | — | 0.01 | 0.01 | 0.03 | — |
Average Payables |
0.27 | 0.30 | 1.79 | 2.01 | 0.56 | 0.34 | 0.33 | 0.28 | 0.15 | — |
Average Inventory |
— | 0.00 | 0.01 | 0.01 | — | — | — | — | — | — |
Average Assets |
7.24 | 8.69 | 14.95 | 15.23 | 5.99 | 0.62 | 0.50 | 0.34 | 0.26 | 0.19 |
Average Common Equity |
6.93 | 8.34 | 13.10 | 13.04 | (14.79) | (23.94) | (6.04) | (3.12) | (1.20) | (0.05) |
Columns are period end dates